Sandra Martinez-Martin
Overview
Explore the profile of Sandra Martinez-Martin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garralda E, Beaulieu M, Moreno V, Casacuberta-Serra S, Martinez-Martin S, Foradada L, et al.
Nat Med
. 2024 Feb;
30(3):762-771.
PMID: 38321218
Among the 'most wanted' targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and maintenance. It has, however, long been considered undruggable. OMO-103...
2.
Martinez-Martin S, Beaulieu M, Soucek L
Cancer Drug Resist
. 2023 Jul;
6(2):205-222.
PMID: 37457123
MYC plays a central role in tumorigenesis by orchestrating cell proliferation, growth and survival, among other transformation mechanisms. In particular, MYC has often been associated with lymphomagenesis. In fact, MYC...
3.
Zacarias-Fluck M, Masso-Valles D, Giuntini F, Gonzalez-Larreategui I, Kaur J, Casacuberta-Serra S, et al.
Genes Dev
. 2023 Apr;
37(7-8):303-320.
PMID: 37024284
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling...
4.
Masso-Valles D, Beaulieu M, Jauset T, Giuntini F, Zacarias-Fluck M, Foradada L, et al.
Cancer Res Commun
. 2023 Mar;
2(2):110-130.
PMID: 36860495
Significance: While MYC role in metastasis has been long controversial, this manuscript demonstrates that MYC inhibition by either transgenic expression or pharmacologic use of the recombinantly produced Omomyc miniprotein exerts...
5.
Beaulieu M, Martinez-Martin S, Kaur J, Castillo Cano V, Masso-Valles D, Foradada Felip L, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765784
MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In...
6.
Martinez-Martin S, Soucek L
Cancer Drug Resist
. 2022 May;
4(4):842-865.
PMID: 35582389
The importance of MYC function in cancer was discovered in the late 1970s when the sequence of the avian retrovirus that causes myelocytic leukemia was identified. Since then, over 40...
7.
Pighi C, Cheong T, Compagno M, Patrucco E, Arigoni M, Olivero M, et al.
Blood Adv
. 2021 Oct;
5(23):5239-5257.
PMID: 34625792
The expression of BCL6 in B-cell lymphoma can be deregulated by chromosomal translocations, somatic mutations in the promoter regulatory regions, or reduced proteasome-mediated degradation. FBXO11 was recently identified as a...
8.
Zacarias-Fluck M, Jauset T, Martinez-Martin S, Kaur J, Casacuberta-Serra S, Masso-Valles D, et al.
Life Sci Alliance
. 2021 Mar;
4(5).
PMID: 33653688
The huge cadre of genes regulated by Myc has obstructed the identification of critical effectors that are essential for Myc-driven tumorigenesis. Here, we describe how only the lack of the...
9.
Beaulieu M, Jauset T, Masso-Valles D, Martinez-Martin S, Rahl P, Maltais L, et al.
Sci Transl Med
. 2019 Mar;
11(484).
PMID: 30894502
Inhibiting MYC has long been considered unfeasible, although its key role in human cancers makes it a desirable target for therapeutic intervention. One reason for its perceived undruggability was the...
10.
Jauset T, Masso-Valles D, Martinez-Martin S, Beaulieu M, Foradada L, Fiorentino F, et al.
Oncotarget
. 2018 May;
9(27):18734-18746.
PMID: 29721157
Effectively treating KRAS-driven tumors remains an unsolved challenge. The inhibition of downstream signaling effectors is a way of overcoming the issue of direct targeting of mutant KRAS, which has shown...